A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Status:
Completed
Trial end date:
2008-01-29
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of
migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.